<p>恩安達製藥公司（NASDAQ:ENTA - 獲取免費報告）的股票在目前覆蓋該公司的五家評級機構中獲得了 “適度買入” 的共識評級，MarketBeat.com 報道。一位股票研究分析師給予該股票賣出評級，三位分析師給予買入評級，一位分析師給予強烈買入評級。在過去一年中，更新了對該股票覆蓋的經紀公司平均一年目標價為 17.25 美元。</p>
<p>獲取 <strong>恩安達製藥</strong> 的提醒：</p>
<p>幾位分析師對該公司進行了評論。JMP Securities 在 2 月 11 日的報告中重申了 “市場表現優於大盤” 的評級，並對恩安達製藥的股票設定了 21.00 美元的目標價。HC Wainwright 在 2 月 11 日的報告中重申了 “買入” 評級，並對恩安達製藥的股票設定了 18.00 美元的目標價。最後，StockNews.com 在 2 月 19 日的研究報告中將恩安達製藥的評級從 “賣出” 上調至 “持有”。</p>
<p><strong>查看我們對 ENTA 的最新分析</strong></p>
<h2>內部活動</h2>
<p>在相關消息中，首席執行官 Jay R. Luly 於 2 月 12 日星期三購買了 45,000 股公司的股票。每股的平均成本為 5.69 美元，總交易額為 256,050.00 美元。收購後，首席執行官現在擁有 846,638 股公司股票，價值 4,817,370.22 美元。這代表了其持股比例的 5.61% 的增長。此次購買已在向 SEC 的備案中披露，您可以通過此鏈接訪問。內部人士持有公司股票的 13.89%。</p>
<h2>機構投資者對恩安達製藥的看法</h2>
<p>一些大型投資者最近增加或減少了對該公司的持股。Krensavage Asset Management LLC 在第三季度將其在恩安達製藥的持股增加了 19.7%。Krensavage Asset Management LLC 現在擁有 1,498,074 股該生物技術公司的股票，價值 15,520,000 美元，此前在上個季度又收購了 246,736 股。RA Capital Management L.P. 在第四季度購買了恩安達製藥的新股份，價值約為 5,968,000 美元。Marshall Wace LLP 在第四季度將其在恩安達製藥的持股增加了 9.3%。Marshall Wace LLP 現在擁有 930,087 股該生物技術公司的股票，價值 5,348,000 美元，此前在上個季度又購買了 79,197 股。Millennium Management LLC 在第四季度將其在恩安達製藥的持股增加了 22.7%。Millennium Management LLC 現在擁有 896,987 股該生物技術公司的股票，價值 5,158,000 美元，此前在上個季度又購買了 165,692 股。最後，Geode Capital Management LLC 在第三季度將其在恩安達製藥的持股增加了 3.1%。Geode Capital Management LLC 現在擁有 477,351 股該生物技術公司的股票，價值 4,946,000 美元，此前在上個季度又購買了 14,575 股。94.99% 的股票由機構投資者和對沖基金持有。</p>
<h2>恩安達製藥股票表現</h2>
<p>恩安達製藥（NASDAQ:ENTA - 獲取免費報告）股票在週五開盤時為 4.73 美元。該公司的市值為 1.0091 億美元，市盈率為-0.96，貝塔值為 0.47。恩安達製藥的 1 年最低價為 4.52 美元，1 年最高價為 17.24 美元。該公司的 50 日移動平均價格為 6.39 美元，200 日移動平均價格為 8.00 美元。</p>
<p>恩安達製藥（NASDAQ:ENTA - 獲取免費報告）最近於 2 月 10 日星期一發布了季度財報。這家生物技術公司報告的每股收益（EPS）為-1.05 美元，超過了市場共識預期的-1.16 美元，超出幅度為 0.11 美元。恩安達製藥的股本回報率為-75.53%，淨利潤率為-157.57%。整體來看，股票分析師預測恩安達製藥在本年度將發佈-4.65 的每股收益。</p>
<h2>關於恩安達製藥</h2>
<p>（獲取免費報告）</p>
<p>恩安達製藥公司是一家生物技術公司，專注於發現和開發用於治療病毒感染和肝病的小分子藥物。其產品管線包括 EDP-514，目前正在進行針對慢性乙型肝炎病毒（HBV）感染的 1b 期臨牀開發；EDP-938 和 EDP-323，目前正在進行針對呼吸道合胞病毒的 II 期臨牀開發；EDP-235，目前正在進行針對人類冠狀病毒的 II 期臨牀開發；以及 Glecaprevir，目前已上市用於治療慢性丙型肝炎病毒（HCV）感染。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比恩安達製藥更好</li>
<li>安靜期到期的解釋</li>
<li>Archer Aviation 在非洲的交易可能會提升 ACHR 股票</li>
<li>天然氣價格繼續上漲，這些股票將受益</li>
<li>空頭賣家對這三隻半導體股票是否錯誤？</li>
<li>八月值得購買的三隻最佳零售股票</li>
<li>波音在三月份獲得 500 億美元訂單——BA 股票現在值得買嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在恩安達製藥嗎？</h2>
<p>在考慮恩安達製藥之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而恩安達製藥並不在名單上。</p>
<p>雖然 Enanta 製藥目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Enanta制藥

<p>Enanta 製藥公司（NASDAQ:ENTA）獲得了五家券商的 “適度買入” 共識評級。一位分析師將其評級為賣出，三位分析師評級為買入，一位分析師評級為強力買入。平均目標價為 17.25 美元。首席執行官 Jay R. Luly 以每股 5.69 美元購買了 45,000 股，增加了他的持股比例。機構投資者持有 94.99% 的股份。Enanta 的股票開盤價為 4.73 美元，市值為 1.0091 億美元。該公司報告的季度每股收益為（1.05 美元），超出預期。Enanta 專注於開發針對病毒感染和肝臟疾病的藥物</p>

<p>Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received a consensus rating of &#34;Moderate Buy&#34; from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $17.25.</p>
<div class="lb-trans"><p>恩安達製藥公司（NASDAQ:ENTA - 獲取免費報告）的股票在目前覆蓋該公司的五家評級機構中獲得了 “適度買入” 的共識評級，MarketBeat.com 報道。一位股票研究分析師給予該股票賣出評級，三位分析師給予買入評級，一位分析師給予強烈買入評級。在過去一年中，更新了對該股票覆蓋的經紀公司平均一年目標價為 17.25 美元。</p>
</div><p>Get <strong>Enanta Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>恩安達製藥</strong> 的提醒：</p>
</div><p>Several analysts have commented on the company. JMP Securities restated a &#34;market outperform&#34; rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised Enanta Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, February 19th.</p>
<div class="lb-trans"><p>幾位分析師對該公司進行了評論。JMP Securities 在 2 月 11 日的報告中重申了 “市場表現優於大盤” 的評級，並對恩安達製藥的股票設定了 21.00 美元的目標價。HC Wainwright 在 2 月 11 日的報告中重申了 “買入” 評級，並對恩安達製藥的股票設定了 18.00 美元的目標價。最後，StockNews.com 在 2 月 19 日的研究報告中將恩安達製藥的評級從 “賣出” 上調至 “持有”。</p>
</div><p><strong>View Our Latest Analysis on ENTA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ENTA 的最新分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In related news, CEO Jay R. Luly bought 45,000 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average cost of $5.69 per share, for a total transaction of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 13.89% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席執行官 Jay R. Luly 於 2 月 12 日星期三購買了 45,000 股公司的股票。每股的平均成本為 5.69 美元，總交易額為 256,050.00 美元。收購後，首席執行官現在擁有 846,638 股公司股票，價值 4,817,370.22 美元。這代表了其持股比例的 5.61% 的增長。此次購買已在向 SEC 的備案中披露，您可以通過此鏈接訪問。內部人士持有公司股票的 13.89%。</p>
</div><h2>Institutional Investors Weigh In On Enanta Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對恩安達製藥的看法</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the company. Krensavage Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company's stock valued at $15,520,000 after acquiring an additional 246,736 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $5,968,000. Marshall Wace LLP raised its position in shares of Enanta Pharmaceuticals by 9.3% in the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after purchasing an additional 79,197 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 22.7% during the 4th quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock valued at $5,158,000 after buying an additional 165,692 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company's stock worth $4,946,000 after buying an additional 14,575 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近增加或減少了對該公司的持股。Krensavage Asset Management LLC 在第三季度將其在恩安達製藥的持股增加了 19.7%。Krensavage Asset Management LLC 現在擁有 1,498,074 股該生物技術公司的股票，價值 15,520,000 美元，此前在上個季度又收購了 246,736 股。RA Capital Management L.P. 在第四季度購買了恩安達製藥的新股份，價值約為 5,968,000 美元。Marshall Wace LLP 在第四季度將其在恩安達製藥的持股增加了 9.3%。Marshall Wace LLP 現在擁有 930,087 股該生物技術公司的股票，價值 5,348,000 美元，此前在上個季度又購買了 79,197 股。Millennium Management LLC 在第四季度將其在恩安達製藥的持股增加了 22.7%。Millennium Management LLC 現在擁有 896,987 股該生物技術公司的股票，價值 5,158,000 美元，此前在上個季度又購買了 165,692 股。最後，Geode Capital Management LLC 在第三季度將其在恩安達製藥的持股增加了 3.1%。Geode Capital Management LLC 現在擁有 477,351 股該生物技術公司的股票，價值 4,946,000 美元，此前在上個季度又購買了 14,575 股。94.99% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Enanta Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>恩安達製藥股票表現</h2>
</div><p>Shares of NASDAQ ENTA opened at $4.73 on Friday. The firm has a market cap of $100.91 million, a P/E ratio of -0.96 and a beta of 0.47. Enanta Pharmaceuticals has a 1 year low of $4.52 and a 1 year high of $17.24. The firm's 50 day moving average price is $6.39 and its 200 day moving average price is $8.00.</p>
<div class="lb-trans"><p>恩安達製藥（NASDAQ:ENTA - 獲取免費報告）股票在週五開盤時為 4.73 美元。該公司的市值為 1.0091 億美元，市盈率為-0.96，貝塔值為 0.47。恩安達製藥的 1 年最低價為 4.52 美元，1 年最高價為 17.24 美元。該公司的 50 日移動平均價格為 6.39 美元，200 日移動平均價格為 8.00 美元。</p>
</div><p>Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, equities analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current year.</p>
<div class="lb-trans"><p>恩安達製藥（NASDAQ:ENTA - 獲取免費報告）最近於 2 月 10 日星期一發布了季度財報。這家生物技術公司報告的每股收益（EPS）為-1.05 美元，超過了市場共識預期的-1.16 美元，超出幅度為 0.11 美元。恩安達製藥的股本回報率為-75.53%，淨利潤率為-157.57%。整體來看，股票分析師預測恩安達製藥在本年度將發佈-4.65 的每股收益。</p>
</div><h2>About Enanta Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於恩安達製藥</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.</p>
<div class="lb-trans"><p>恩安達製藥公司是一家生物技術公司，專注於發現和開發用於治療病毒感染和肝病的小分子藥物。其產品管線包括 EDP-514，目前正在進行針對慢性乙型肝炎病毒（HBV）感染的 1b 期臨牀開發；EDP-938 和 EDP-323，目前正在進行針對呼吸道合胞病毒的 II 期臨牀開發；EDP-235，目前正在進行針對人類冠狀病毒的 II 期臨牀開發；以及 Glecaprevir，目前已上市用於治療慢性丙型肝炎病毒（HCV）感染。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Enanta Pharmaceuticals</li>
<li>Quiet Period Expirations Explained</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>Natural Gas Prices Continue To Rally, These Stocks Should Benefit</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>The 3 Best Retail Stocks to Shop for in August</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比恩安達製藥更好</li>
<li>安靜期到期的解釋</li>
<li>Archer Aviation 在非洲的交易可能會提升 ACHR 股票</li>
<li>天然氣價格繼續上漲，這些股票將受益</li>
<li>空頭賣家對這三隻半導體股票是否錯誤？</li>
<li>八月值得購買的三隻最佳零售股票</li>
<li>波音在三月份獲得 500 億美元訂單——BA 股票現在值得買嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ENTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Enanta Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在恩安達製藥嗎？</h2>
</div><p>Before you consider Enanta Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮恩安達製藥之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而恩安達製藥並不在名單上。</p>
</div><p>While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Enanta 製藥目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Enanta 製藥公司（納斯達克股票代碼：ENTA）獲得券商的 “適度買入” 平均推薦